Defense Dynamics: Navigating the Post-Election Landscape for the National Security Sector
Ask a CFIUS Expert: Is Crypto Spying on Us?
Hot Topics in International Trade-Braumiller Law Group-FDI Into Mexico from China
4 Key Takeaways | Solar Industry & Chinese Tariff Update
10 Key Trade Developments: Trade Remedy Cases
Episode 309 -- Alex Cotoia on Compliance with the Uyghur Forced Labor Prevention Act
10 Key Trade Developments: China
Noteworthy Points in the Rules for the Implementation of China's Patent Law 2023
JONES DAY TALKS®: Corporate Compliance in Asia: Managing Rapid Regulatory Change and Ambiguity
Hot Topics in International Trade. Braumiller Law Group Partner & Founder Adrienne Braumiller joins Vp of Marketing Bob Brewer for an Update on Forced Labor
Episode 292 -- 3M's $6.5 Million FCPA Settlement with the SEC
5 Key Takeaways | How to Effectively Leverage the Chinese Patent System
Third Party Observation in Patent Prosecution in China
The Grace Period for Novelty in Chinese Patent Law
One Month to a More Effective Compliance Program with Boards – Day 14 - Boards and Doing Business in China
Episode 276 -- Review of Phillips and Franks Int'l SEC FCPA Settlements
Sanction and the Increasing Complexity of Trade Compliance
Braumiller Law Group Help With China Imports
Coming Conflict with China: Part 5 - Good Compliance Is Good Business
JONES DAY PRESENTS®: Taiwan's Enhanced Trade Secret Restrictions and Stricter Penalties
As reported in our previous client alert, on May 14, 2024, President Biden announced that he directed his Trade Representative to increase tariffs under Section 301 of the Trade Act of 1974 (Section 301) on a wide range of...more
On May 27, 2022, the Office of the US Trade Representative (USTR) published a Federal Register notice extending Section 301 tariff exclusions for certain China-origin medical products needed to address the COVID-19 pandemic....more
As the country continues to experience the effects of the COVID-19 pandemic, the Office of the US Trade Representative (USTR) has invited public comments on whether to continue excluding certain medical supplies from the...more
On March 10, 2021, the United States Trade Representative (USTR) published an extension of the COVID-19 related medical-care and response product exclusions from Section 301 duties covering imports from China. The agency...more
On December 29, 2020, the U.S. Trade Representative (USTR) posted a notice granting new Section 301 product exclusions and extending existing exclusions for COVID-19 medical care products. This action is in response to USTR’s...more
The Office of the U.S. Trade Representative (USTR) has issued a call for comments regarding the possible removal of Section 301 tariffs for medical-care products from China. The request for comments on the easing of Section...more
The Office of the U.S. Trade Representative (USTR) has announced it is accepting comments on potential Section 301 tariff exclusions for Chinese imports necessary to respond to the coronavirus. USTR is likely to expeditiously...more
On March 25, 2020, the Office of the U.S. Trade Representative (USTR) published a Federal Register Notice requesting public comments on possible further modifications to remove Section 301 duties from additional...more
The Office of the U.S. Trade Representative (USTR) recently published several Federal Register Notices (March 10, 16, and 17, 2020) announcing new granted exclusions for List 3 goods (currently 25 percent) and List 4A goods...more
The Office of the U.S. Trade Representative (USTR) has issued two separate notices of interest to U.S. importers caught in the U.S.-China trade war and that are seeking relief through Section 301 tariff exclusions....more